EUVIMEDObjevte EUVIMED
Crossref

Mechanisms involved in the antiplatelet activity of ketamine in human platelets

Yi Chang, Ta-Liang Chen, Gong-Jhe Wu, George Hsiao, Ming-Yi Shen, Kuan-Hung Lin, Duen-Suey Chou, Chien-Huang Lin, Joen-Rong Sheu

Journal of Biomedical Science · 2004-11 · 11 (6) · 764-772

DOI: 10.1007/bf02254361 ↗

At a glance

Journal article in Journal of Biomedical Science, 2004-11. Written by Yi Chang and 8 co-authors. Institution: Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, ROC. Cited 22 times so far (Crossref); 33 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The aim of this study was to systematically examine the inhibitory mechanisms of ketamine in platelet aggregation. In this study, ketamine concentration-dependently (100-350 microM) inhibited platelet aggregation both in washed human platelet suspensions and platelet-rich plasma stimulated by agonists. Ketamine inhibited phosphoinositide breakdown and intracellular Ca2+ mobilization in human platelets stimulated by collagen. Ketamine (200 and 350 microM) significantly inhibited thromboxane (Tx) A2 formation stimulated by collagen. Moreover, ketamine (200 and 350 microM) increased the fluorescence of platelet membranes tagged with diphenylhexatriene. Rapid phosphorylation of a platelet protein of Mr 47,000 (P47), a marker of protein kinase C activation, was triggered by phorbol-12,13-dibutyrate (100 nM). This phosphorylation was markedly inhibited by ketamine (350 microM). These results indicate that the antiplatelet activity of ketamine may be involved in the following pathways. Ketamine may change platelet membrane fluidity, with a resultant influence on activation of phospholipase C, and subsequent inhibition of phosphoinositide breakdown and phosphorylation of P47, thereby leading to inhibition of intracellular Ca2+ mobilization and TxA2 formation, ultimately resulting in inhibition of platelet aggregation.

Subjects

MeSH terms (MEDLINE)

Blood PlateletsCalciumCell MembraneCollagenCyclic AMPCyclic GMPCytosolDose-Response Relationship, DrugExcitatory Amino Acid AntagonistsFlow CytometryFura-2HumansKetamineL-Lactate DehydrogenaseMicroscopy, FluorescencePhorbol 12,13-DibutyratePhosphorylationPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa Complex

Substances

Excitatory Amino Acid AntagonistsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPhorbol 12,13-DibutyrateThromboxane B2Thromboxane A2KetamineCollagenCyclic AMPL-Lactate Dehydrogenase

Authors and institutions

  • Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, ROC.

Cite

APA

Chang, Y., Chen, T. L., Wu, G. J., Hsiao, G., Shen, M. Y., Lin, K. H., Chou, D. S., Lin, C. H., & Sheu, J. R. (2004). Mechanisms involved in the antiplatelet activity of ketamine in human platelets. Journal of Biomedical Science, 11(6), 764-772. https://doi.org/10.1007/bf02254361

Vancouver

Chang Y, Chen TL, Wu GJ, Hsiao G, Shen MY, Lin KH, et al. Mechanisms involved in the antiplatelet activity of ketamine in human platelets. Journal of Biomedical Science. 2004;11(6):764-772. doi:10.1007/bf02254361

BibTeX
@article{Chang2004,
  author = {Chang, Yi and Chen, Ta-Liang and Wu, Gong-Jhe and Hsiao, George and Shen, Ming-Yi and Lin, Kuan-Hung and Chou, Duen-Suey and Lin, Chien-Huang and Sheu, Joen-Rong},
  title = {Mechanisms involved in the antiplatelet activity of ketamine in human platelets},
  journal = {Journal of Biomedical Science},
  year = {2004},
  volume = {11},
  number = {6},
  pages = {764--772},
  doi = {10.1007/bf02254361}
}
Start for free →